Mirtazapin Actavis (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing postsynaptic 5‑HT2 and 5‑HT3 receptors. This dual action enhances the overall availability of norepinephrine and serotonin, neurotransmitters that play key roles in mood regulation.

The appropriate dose of Mirtazapin Actavis is determined by the prescribing clinician based on the individual patient's clinical condition, response to therapy, and tolerability. Dosage may be adjusted over time, and patients should follow the specific instructions provided by their healthcare professional.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mirtazapin Actavis belongs to the NaSSA class, which differs from selective serotonin reuptake inhibitors (SSRIs) by also enhancing norepinephrine release and blocking certain serotonin receptors. This mechanism often results in a distinct side‑effect profile, such as higher rates of sedation and weight gain, but may be advantageous for patients who do not respond adequately to SSRIs.

Store the tablets at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Mirtazapin Actavis is taken orally, and the tablets can be swallowed whole, placed under the tongue (sublingual), or held in the buccal cavity before swallowing, depending on the prescriber's instructions. It is usually taken once daily, preferably in the evening to take advantage of its sedative effect.

Serious risks include the potential for agranulocytosis or severe neutropenia, emergence or worsening of suicidal thoughts especially early in treatment, serotonin syndrome when combined with other serotonergic drugs, severe allergic reactions such as Stevens‑Johnson syndrome, and hepatic dysfunction. Patients should be monitored closely for any of these events.

Mirtazapin Actavis is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and in individuals currently taking monoamine oxidase inhibitors (MAOIs) or who have used an MAOI within the past 14 days. Caution is also advised for patients with severe hepatic impairment or uncontrolled bipolar disorder.